X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
PANACEA BIOTEC LIMITED Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

PANACEA BIOTEC LIMITED  (PANB)


Here is the latest financial fact sheet of Panacea Biotech. For more details, see the Panacea Biotech quarterly results and Panacea Biotech share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
panacea biotech - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 155.0       No. of shares m 61.25
    Mkt Cap Rs m 9,494       % ch % 1.3
    Vol '000 19.0       % ch week % -2.6
    P/E X 83.4       % ch 1-mth % 0.8
    P/CF X -22.9       % ch 12-mth % 63.8
    EPS (TTM) Rs 1.9       52 week H/L Rs 178.3/85.5
(As on Mar 23, 2017 03:36:00 PM) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-10
*
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs248241195159149 
Low Rs59152686482 
Sales per share (Unadj.) Rs134.7189.8115.999.384.1 
Earnings per share (Unadj.) Rs12.223.6-33.6-38.2-18.3 
Diluted earnings per shareRs13.323.6-33.6-38.2-18.3 
Cash flow per share (Unadj.) Rs19.735.8-21.0-24.2-6.7 
Dividends per share (Unadj.) Rs0.250.75000 
Adj. dividends per shareRs0.270.750.000.000.00 
Dividend yield (eoy) %0.20.4000 
Book value per share (Unadj.) Rs104.8105.9142.9102.283.7 
Adj. book value per shareRs114.4105.9142.9102.283.7 
Shares outstanding (eoy) m66.8461.2561.2561.2561.25 
Bonus/Rights/Conversions  ESOPBB--- 
Price / Sales ratio x1.11.01.11.11.4 
Avg P/E ratio x12.68.3-3.9-2.9-6.3 
P/CF ratio (eoy) x7.85.5-6.3-4.6-17.2 
Price / Book Value ratio x1.51.90.91.11.4 
Dividend payout %2.03.2000 
Avg Mkt Cap Rs m10,26012,0368,0546,7997,074 
No. of employees `0003.23.63.33.32.8 
Total wages/salary Rs m1,2721,6081,6071,4691,449 
Avg. sales/employee Rs Th2,787.93,229.82,151.81,843.91,874.1 
Avg. wages/employee Rs Th393.9446.7487.0445.3527.0 
Avg. net profit/employee Rs Th253.0401.9-623.2-709.9-407.7 
  INCOME DATA
Net Sales Rs m9,00211,6277,1016,0855,154 
Other income Rs m9361618854100 
Total revenues Rs m9,93811,7887,1896,1395,254 
Gross profit Rs m1,1702,549-863-861-766 
Depreciation Rs m500745771860711 
Interest Rs m3854731,0071,0381,503 
Profit before tax Rs m1,2211,492-2,553-2,704-2,881 
Minority Interest Rs m000011 
Prior Period Items Rs m-2-6-450-6 
Extraordinary Inc (Exp) Rs m017301731,771 
Tax Rs m402212-542-18817 
Profit after tax Rs m8171,447-2,057-2,343-1,121 
Gross profit margin %13.021.9-12.2-14.1-14.9 
Effective tax rate %32.914.221.26.9-0.6 
Net profit margin %9.112.4-29.0-38.5-21.8 
  BALANCE SHEET DATA
Current assets Rs m7,4958,1375,0154,3383,810 
Current liabilities Rs m2,0215,7615,1655,1008,365 
Net working cap to sales %60.820.4-2.1-12.5-88.4 
Current ratio x3.71.41.00.90.5 
Inventory Days Days186129198161156 
Debtors Days Days4487354267 
Net fixed assets Rs m8,6348,03612,85912,89814,480 
Share capital Rs m6761616161 
"Free" reserves Rs m6,9276,4244,3732,024903 
Net worth Rs m7,0056,4888,7516,2575,127 
Long term debt Rs m3,0854,2375,1256,8995,832 
Total assets Rs m16,85617,33919,49818,39519,433 
Interest coverage x4.24.2-1.5-1.6-0.9 
Debt to equity ratio x0.40.70.61.11.1 
Sales to assets ratio x0.50.70.40.30.3 
Return on assets %7.111.1-5.4-7.12.0 
Return on equity %11.722.3-23.5-37.4-21.9 
Return on capital %15.919.9-11.5-11.33.6 
Exports to sales %71.861.148.414.924.5 
Imports to sales %39.425.234.06.310.2 
Exports (fob) Rs m6,4657,1043,4379051,264 
Imports (cif) Rs m3,5442,9312,411385525 
Fx inflow Rs m6,5117,1463,4731,2071,539 
Fx outflow Rs m3,8923,3953,045954942 
Net fx Rs m2,6193,751428253597 
  CASH FLOW
From Operations Rs m 622 780 2,281 -240 599 
From Investments Rs m -1,172 120 -1,239 -612 -438 
From Financial Activity Rs m 276 -852 -1,336 1,049 -303 
Net Cashflow Rs m -275 49 -295 197 -141 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for panacea biotec limited

 Share Holding
Indian Promoters : 74.5%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 0.6%
FIIs : 1.3%
ADR/GDR : 0.0%
Free float : 23.6%
Shareholders : 10,259
Pledged promoter(s) holding : 35.1%
 Company Information
Top
    REGD OFF: Ambala - Chandigarh Highway, Lalru, Punjab - 140 501
    E-MAIL: companysec@panaceabiotec.com     WEB: www.panaceabiotec.com
    TELEPHONE: (011) 4157 8024     FAX: (011) 4167 9070
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Skyline Financial, D-153 A, Ist Flr., Okhla Indl. Area, Phase-I, New Delhi-20
    AUDITOR: S. R. Batliboi & Co.
CHM: Soshil Kumar Jain COMP SEC: Vinod Goel (GM-Legal) YEAR OF INC: 1985 BSE CODE: 531349 FV (Rs): 1 DIV YIELD (%): -

More pharmaceuticals Company Fact Sheets:   TTK HEALTHCARESHASUN PHARMALUPIN LTDWYETH LTDRANBAXY LAB


Today's Market

Sensex Remains Firm; Energy Stocks Lead Gains(01:30 pm)

After opening the day on a positive note, share markets in India have continued the momentum and are trading marginally above the dotted line. Sectoral indices are trading on a positive note with stocks in the oil and gas sector.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

As Digital Transactions Fall, Indians Are Going Back to Cash(Vivek Kaul's Diary)

Mar 16, 2017

Digital transactions have fallen since December 2016 both in value and volume terms.

Stock Markets and Gold Rally, Dollar Tumbles(Chart Of The Day)

Mar 16, 2017

Markets are moving up even after the fed interest rate hike.

Why You Should Try SCOREFASTTM Right Now(Daily Profit Hunter)

Mar 10, 2017

Asad Dossani discusses why SCOREFASTM will be a successful trading strategy

4 Things To Watch Out For After Modi's Landslide Win In UP Polls(Outside View)

Mar 15, 2017

PersonalFN explains why you need to wary while investing in equities despite Modi's UP win.

More

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - SUVEN LIFE COMPARISON

Compare Company With Charts

COMPARE PANACEA BIOTECH WITH

MARKET STATS